Category: Uncategorized

A laboratory identification of methamphetamine does not necessarily identify its source. Chiral testing asks an additional question: which mirror-image form, or mixture of forms, is present?

Chemical identity and stereochemistry

Barry Logan’s 2002 forensic review distinguishes the d- and l-forms of methamphetamine and explains that stereochemistry affects pharmacological activity. An assay reporting total methamphetamine may not resolve those forms. The laboratory must use an appropriate stereospecific method if the distinction is important.

A confirmed total-drug result and a resolved isomer result answer different analytical questions. Neither should be described as if it necessarily supplies the other.

Medication-related explanations require specific evidence

The review discusses several pathways by which medicines can produce amphetamine-related findings. It describes selegiline metabolism to l-methamphetamine and l-amphetamine, and benzphetamine metabolism that can yield d-methamphetamine and amphetamine. These examples show why finding the d-form alone does not uniquely identify an illicit supply.

Logan also discusses historical decongestant preparations containing l-methamphetamine. That discussion concerns products and evidence available in 2002; it is not a statement about every currently sold inhaler or its formulation.

What to request from the laboratory

A useful evaluation identifies the specimen, confirmed analytes, concentrations, reporting limits and whether chiral separation was performed. If percentages are reported, the interpretation should consider quantification near the reporting limits and the validation of the specific method.

Medication records and timing can then be compared with the chemistry. Where a parent medicine or a more specific metabolite can distinguish explanations, those additional measurements may be more informative than an isomer label by itself. An untested alternative remains an alternative, rather than a demonstrated explanation.

Source attribution is separate from impairment

Even a well-supported source opinion does not establish the degree of functional impairment at an earlier event. That requires additional evidence about exposure history, observations and timing. Conversely, a lawful source does not itself establish unimpaired performance.

The defensible conclusion is conditional: stereochemistry can narrow a source assessment, but a particular isomer pattern must be interpreted with the complete analytical and medication record.

Scientific source

Logan BK. Methamphetamine—Effects on Human Performance and Behavior. Forensic Science Review. 2002;14(1–2):133–151. This article analyzes the supplied historical review; studies discussed within that review are secondary-source evidence here.

Similar methamphetamine blood concentrations can accompany markedly different behavior. A two-case report by Nikolas P. Lemos illustrates why a concentration must be interpreted alongside the driving observations, collection time and circumstances.

The comparison

In the first case, an officer observed tailgating and abrupt, unsignaled lane changes at approximately 30–35 miles per hour. The driver was described as cooperative, although the report documented abnormal speech, elevated pulse and errors during administered tasks. Blood collected about 80 minutes after driving contained 0.66 mg/L methamphetamine and 0.17 mg/L amphetamine.

The second case involved a pursuit exceeding 100 miles per hour, continued driving after a tire failure, flight and aggressive resistance. Blood collected about 90 minutes after the observed driving contained 0.51 mg/L methamphetamine and 0.10 mg/L amphetamine. No field sobriety tests were performed in that case.

What the numbers support

The measurements establish reported concentrations in the collected blood specimens. They were not contemporaneous measurements during driving. The two methamphetamine values were numerically similar rather than identical, and the higher value belonged to the cooperative driver.

That comparison challenges an assumption that progressively higher concentrations must produce progressively more aggression. Cooperation also did not mean normal driving: the first driver’s reported lane changes and following distance still required examination.

What two cases cannot establish

This was a descriptive case report, not a controlled dose-response experiment. The drivers differed in circumstances, and the investigation did not hold sleep, prior exposure, tolerance or other relevant variables constant. Two selected cases cannot establish population risk, an impairment cutoff or the predictive accuracy of a behavioral sign.

The paper described both cases as impaired driving. Recognizing the limits of concentration-based prediction does not reverse that description or prove either driver was unimpaired. It defines what the comparison can support scientifically.

Questions for evaluating similar evidence

Separate the driving record from the later examination. Identify the exact specimen, both analytes, collection interval, screening and confirmation methods, and any limitations of the tested panel. Then ask whether the proposed opinion addresses exposure, performance or causation; those are distinct conclusions.

Scientific source

Lemos NP. Methamphetamine and driving. Science and Justice. 2009;49:247–249. Original case report.

A large increase in apparent oral clearance does not necessarily mean that systemic clearance increased by the same amount. Oral exposure also depends on how much drug reaches systemic circulation. A midazolam microdose study shows why those quantities must remain separate when interpreting an enzyme-inducing interaction.

Two routes answer different questions

Hohmann and colleagues used oral and intravenous midazolam to investigate induction of CYP3A activity by a specified St. John’s wort preparation, followed by the addition of rifampin. Eleven healthy volunteers completed the study. Oral midazolam was administered first; on selected study days an intravenous microdose followed six hours later.

The oral calculation yields apparent clearance, CL/F, where F is bioavailability. Intravenous administration permits estimation of systemic clearance because the dose enters systemic circulation directly. A rise in CL/F can therefore reflect increased systemic clearance, reduced bioavailability, or both. It is not interchangeable with the intravenous clearance estimate.

The route difference was substantial

At the highest St. John’s wort regimen, the full-profile analysis showed apparent oral clearance approximately 4.62 times baseline, while systemic clearance was approximately 2.05 times baseline. Estimated absolute bioavailability fell from 35.1% to 15.6%.

After rifampin was added, apparent oral clearance was approximately 14.14 times baseline and systemic clearance approximately 2.93 times baseline. Estimated bioavailability fell further to 7.28%. These are study-specific research results, not instructions for changing a medication dose.

The larger oral change supported an important contribution from metabolism before systemic entry. The authors attributed much of the additional effect to extrahepatic metabolism, likely in the gut. That attribution involved estimates and assumptions; the study did not directly measure intestinal enzyme activity in tissue.

Match the number to the method

The investigators also used a limited-sampling method to estimate partial metabolic clearance. That method produced different fold-change values from the full-profile CL/F calculation. Quoting a fold change without naming the parameter and method risks treating distinct estimates as the same measurement.

The intravenous analysis also corrected for residual exposure from the preceding oral dose. The two administrations were separated in time, but the analysis still had to account for their contributions to the measured concentration history.

What the study cannot settle

The trial used an open, fixed sequence without washout phases between the increasing inducer regimens. It did not include a contemporaneous rifampin-only arm. Comparisons suggesting that the stronger inducer dominated therefore also relied on earlier research; this trial alone cannot establish every aspect of the interaction between the two inducers.

The St. John’s wort preparation and its hyperforin content matter. These results cannot be assigned unchanged to every herbal product, every CYP3A substrate or every patient. Nor does a midazolam microdose establish an individual’s sedation or clinical outcome.

The pharmacokinetic lesson is precise: report the administration route, distinguish CL/F from systemic clearance, and preserve bioavailability in the interpretation. Otherwise, an oral concentration change can be mistaken for a much larger change in systemic elimination than the intravenous evidence supports.

Source

Hohmann N, Friedrichs AS, Burhenne J, Blank A, Mikus G, Haefeli WE. Dose-dependent induction of CYP3A activity by St. John’s wort alone and in combination with rifampin. Clinical and Translational Science. 2024;17:e70007. Read the primary study. Original commentary on the supplied paper; no figures or tables reproduced.

A receptor-binding experiment can support a hypothesis about drug action without establishing how the drug works in patients. The distinction is important when a laboratory affinity estimate is used to predict a clinical effect or dose.

Philip Seeman’s 2016 paper examined cannabidiol (CBD) in rat striatal tissue. Its title proposed partial agonism at dopamine D2High receptors and a prediction of an antipsychotic dose. The evidence should be assessed at the level of the experiment actually performed.

What the assay measured

The study tested whether CBD competed with a radiolabeled compound, tritiated domperidone, for binding in rat brain-tissue preparations. Five independent experiments contributed to the reported competition results.

With that radioligand, the author observed a two-phase competition pattern and calculated different affinity estimates for high- and low-affinity components. The paper interpreted the pattern as similar to that of a known partial agonist.

This was a binding experiment in prepared tissue. It was not a trial administering CBD to patients, a human receptor-occupancy scan or a direct clinical assessment of symptom change.

The radioligand affected the observed pattern

The paper also reported that CBD competition against a different radioligand, tritiated raclopride, did not produce the same two-phase pattern. That result makes the assay conditions relevant to interpretation.

A binding constant is conditional on the experimental system and analysis. It should not be treated as a universal concentration threshold at which a particular patient experiences a defined drug effect.

Binding and functional response are separate questions

The proposed partial-agonist interpretation relied on the binding pattern and comparison with prior pharmacology. The experiment did not directly measure a full CBD-induced receptor-signaling response in these preparations.

That distinction limits the conclusion. Competition for binding can motivate functional testing, but the binding curve alone does not quantify a clinical response or establish that this receptor interaction causes a therapeutic effect.

Clinical dose extrapolation requires additional evidence

The author related laboratory affinity to clinical doses reported in other studies and made assumptions about available drug concentrations. Those extrapolations were not direct measurements of human brain occupancy in this experiment.

The paper therefore supports discussing a historical receptor hypothesis. It does not independently establish an effective treatment dose, demonstrate efficacy in a new patient population or justify changing medication.

The practical lesson is to preserve the chain of inference: tissue binding, receptor function, human exposure, target engagement and clinical outcome require distinct evidence. A result at the first step does not automatically establish the remaining steps.

Source: Seeman P. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational Psychiatry. 2016;6:e920.

A plasma concentration alone does not reveal what fraction of an oral dose reached systemic circulation. Estimating absolute bioavailability requires a reference exposure and attention to the amount administered by each route.

A historical evacetrapib study by Cannady and colleagues illustrates the method. The investigators combined an oral dose with a much smaller intravenous dose labeled using a stable carbon isotope, allowing the laboratory to distinguish the two sources of drug in plasma.

Two routes studied at the same time

Eight healthy adults, seven men and one woman, completed the open-label study. Each received a 130 mg oral evacetrapib tablet while an intravenous infusion delivered approximately 175 micrograms of carbon-13-labeled evacetrapib over four hours. Samples were collected through 168 hours.

The labeled tracer was measured separately from unlabeled evacetrapib using high-performance liquid chromatography with tandem mass spectrometry. The carbon-13 label was stable rather than radioactive.

Simultaneous administration reduced the problem of comparing clearance on different study days. The interpretation still depended on the labeled and unlabeled drug having comparable disposition under the study conditions.

Why raw concentrations would give the wrong comparison

The oral and intravenous doses differed greatly. Their unadjusted concentrations or exposure areas therefore could not be compared as though equal amounts had been administered.

The researchers divided each area under the concentration-time curve by the corresponding dose. They then compared dose-normalized oral exposure with dose-normalized intravenous exposure. The intravenous route supplied the reference for drug entering systemic circulation.

Using exposure extrapolated to infinity, the estimated absolute bioavailability was 44.8%, with a 90% confidence interval of 42.2% to 47.6%. The estimate based on exposure through the last measurable concentration was similar, at 44.3%.

Bioavailability is not the same as absorption alone

The result describes systemic availability under the tested conditions. It does not, by itself, separate incomplete gastrointestinal absorption from loss before the drug reaches systemic circulation. Additional evidence is needed to distinguish those contributions.

It also does not mean that an oral dose was 44.8% effective, or that the result is a therapeutic target. Bioavailability describes drug disposition, not the magnitude of clinical benefit.

The delivered dose required verification

Preliminary work showed that evacetrapib could bind to infusion equipment. The researchers conditioned the infusion system and measured solution exiting the line before and after administration to determine the delivered tracer dose. Nominal preparation concentration alone would have been insufficient.

This detail matters because the intravenous dose appears in the denominator of the exposure comparison. A sophisticated analytical assay cannot compensate for an incorrectly characterized delivered dose.

Limits of the result

This was a small, single-dose study of a particular formulation in healthy adults. It does not establish bioavailability for other formulations, patients with organ impairment or an unknown individual’s dosing circumstances. Its value here is methodological: a valid bioavailability estimate requires the route, delivered dose, exposure interval and comparison assumptions to remain explicit.

Source: Cannady EA and colleagues. Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous carbon-13-labeled evacetrapib as a tracer. Journal of Labelled Compounds and Radiopharmaceuticals. 2016;59:238-244. PubMed record.

A drug’s effect need not increase steadily with dose. Demonstrating a curved dose-response relationship, however, requires more than finding a statistically significant result at one dose and nonsignificant results at two others. A small cannabidiol study illustrates both the pharmacodynamic question and the limits of the evidence.

Three doses, one laboratory stress task

Linares and colleagues studied 57 healthy men in a randomized, double-blind experiment published in the Brazilian Journal of Psychiatry in 2019. Participants received a single oral dose of cannabidiol (CBD) in corn-oil capsules or matching placebo. The 150 mg and 300 mg groups each contained 15 participants, the 600 mg group contained 12, and the placebo group contained 15.

The participants prepared and delivered a speech in front of a camera. Investigators measured subjective mood at several stages and recorded blood pressure. The pharmacodynamic question concerned changes in anxiety during an induced stress task, rather than drug absorption, clearance or concentration-time modeling.

What the anxiety result showed

The 300 mg group reported lower anxiety than placebo during the speech phase in a reported post hoc comparison, with p = 0.042. The 150 mg and 600 mg groups did not show significant differences from placebo on the reported mood-scale comparisons. The authors described the pattern as consistent with an inverted U-shaped dose-response curve.

That description needs qualification. The repeated-measures analysis reported no statistically significant group-by-phase interaction, with p = 0.1. The methods described phase-specific comparisons as following a significant interaction, yet the results reported those comparisons despite the nonsignificant interaction. This discrepancy limits confidence in a strong dose-response conclusion.

A significant placebo comparison at 300 mg and nonsignificant comparisons at other doses do not themselves establish that 300 mg was significantly better than both other doses. Nor do three active doses identify a universal optimum.

Different outcomes remained distinct

The study did not find significant group or group-by-phase effects for systolic or diastolic blood pressure. The mood-scale factors labeled sedation, cognitive impairment and distress also showed no significant effects. These were subjective scale outcomes, not a comprehensive objective assessment of cognition or driving performance.

Consequently, the anxiety signal cannot be generalized into a demonstrated improvement across all physiological or functional measures. A nonsignificant sedation score also does not certify that an individual can drive safely.

Limits on applying the findings

Only healthy men participated, and treatment involved one dose during one experimental session. The results do not directly establish long-term treatment efficacy in patients with anxiety disorders, effects in women, or equivalent effects from other preparations. The authors acknowledged the small sample and the need for larger studies.

The paper discussed receptor-based explanations for the proposed curve, drawing on other research. It did not directly establish a receptor mechanism in these participants. Several authors disclosed CBD-related patent or industry relationships, and the study drug was supplied without charge.

The defensible conclusion is narrow: one dose produced a reported anxiety signal under particular experimental conditions, with statistical and design limitations that prevent converting it into an individualized dosing rule.

Source: Linares IM and colleagues. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry. 2019;41(1):9-14. PubMed record.

Short answer: A positive THC blood or serum test does not establish whether someone used prescribed medical cannabis or nonmedical cannabis. In a published pilot study that measured 18 cannabinoids and metabolites in serum, researchers found potentially informative patterns after certain specific medicines, including dronabinol and nabiximols (Sativex), but THC-rich medical cannabis and street cannabis could not be reliably distinguished. A chemical pattern can be consistent with a product or route of administration without proving its origin in an individual case.

Myth: A THC-positive blood test identifies the source of cannabis

Evidence: Delta-9-tetrahydrocannabinol (THC) is not a label identifying where the substance was obtained. Medicinal and nonmedical cannabis can contain the same principal cannabinoids, and biological testing measures chemical compounds in a specimen—not a prescription, supplier, purchase, or legal status.

In a 2021 pilot study, Scheunemann and colleagues investigated whether serum cannabinoid profiles might distinguish users of particular cannabis-based medicines from people using street cannabis. They analyzed 18 cannabinoids and metabolites with liquid chromatography–tandem mass spectrometry (LC-MS/MS), examined 56 serum samples from 23 study participants, and compared patterns with 55 previously analyzed forensic serum samples from street cannabis users. The central finding was narrower than an ability to “identify medical marijuana”: some formulation-related patterns were informative, but profiles from THC-rich medical cannabis and street cannabis substantially overlapped. Scheunemann et al., Metabolites (2021), DOI: 10.3390/metabo11050316.

What is a serum cannabinoid fingerprint?

A serum cannabinoid profile is a set of measured concentrations—or ratios—of cannabinoids and their metabolites in serum, the liquid fraction obtained after blood has clotted. Unlike a report limited to THC, an expanded panel may measure THC; 11-hydroxy-THC (THC-OH); 11-nor-9-carboxy-THC (THC-COOH); cannabidiol (CBD); cannabichromene (CBC); cannabigerol (CBG); and other minor cannabinoids or acidic precursors.

A profile describes the composition of the tested specimen at collection. An inference about the product, route, or dose additionally depends on pharmacokinetics, the time since exposure, prior use, the analytical method, the product’s changing composition, and alternative explanations. Findings from serum should not be transferred uncritically to venous whole blood, dried blood spots, urine, or oral fluid.

Myth: A high 11-hydroxy-THC-to-THC ratio proves dronabinol use

Evidence: The pilot study observed THC-OH/THC ratios of approximately 1 or more in the dronabinol and Sativex groups, while ratios were generally lower after inhaled plant cannabis. Such ratios may be compatible with a medicine and its route of administration, but they are not a validated universal cutoff that proves a named product, a lawful prescription, or a particular dose.

Interpretation is especially sensitive to route and timing: oral ingestion and inhalation create different concentration–time profiles, and both the numerator and denominator of a ratio change after use. The study was exploratory and did not establish the sensitivity, specificity, or error rate of a casework decision rule for all users. No single ratio should be presented to a jury as product-source identification without independent validation. Primary study.

Myth: CBD or minor cannabinoids prove a product was medical—or illicit

Evidence: The study reported CBD and CBC patterns that sometimes helped distinguish the THC/CBD oromucosal medicine Sativex from certain THC-dominant cannabis samples. Dronabinol samples generally contained relatively few minor cannabinoids. Plant cannabis could show higher levels of some minor constituents, including THCAA or CBGA. But these observations did not furnish a binary test for “legal medicine” versus “street cannabis.”

Two limits are crucial. First, the authors detected trace minor cannabinoids even in some samples from users of cannabis-based medicines. Their presence therefore cannot, by itself, establish additional illicit plant exposure. Second, medical cannabis flower and street cannabis can have overlapping botanical chemistry. The researchers could not separate the THC-rich medical-flower users from the street-cannabis group by their serum patterns. One sample after use of a CBD-rich medical strain appeared distinct, a hypothesis-generating result that was not proof of reliable strain attribution across patients. Source and study limitations.

What the actual evidence supports: a comparison

Laboratory finding	Potentially supportable interpretation	Claim the study does not establish
THC detected in serum	THC was present in that serum specimen.	That the source was recreational rather than medicinal, or that the person was impaired at the time of an event.
THC-OH/THC ratio near or above 1	May resemble patterns observed after some oral/oromucosal formulations in this pilot sample.	Confirmed dronabinol, Sativex, dose, or prescription compliance.
CBD and CBC alongside THC	May add information about formulation composition when combined with other analytes and context.	A unique marker of Sativex or a particular cannabis strain.
Numerous measurable minor cannabinoids	May fit exposure to a plant-derived mixture.	That the plant material was obtained unlawfully or could not be prescribed.
Few or undetected minor cannabinoids	May fit certain purified or THC-dominant products within assay limits.	That plant material was definitively not used.

Myth: A multivariate model converts a suggestive pattern into definitive source identification

Evidence: The researchers used principal component analysis (PCA) and statistical comparisons to visualize differences among groups. PCA can help find structure in a multidimensional dataset; it does not automatically provide a prospectively validated individual-case classifier. The study also tested nine forensic serum samples from people reporting cannabis-based medicine use. Only one sample had a pattern consistent with the declared dronabinol use; the others resembled cannabis-user patterns, leading the investigators to consider possible additional exposure. Those findings remain interpretive, not conclusive proof that an individual misreported medication use.

The study’s limitations matter in litigation: it involved 23 participants and repeated samples from some individuals; medication use, timing, and additional cannabis exposure were largely self-reported; routes, doses, and sampling intervals varied; and knowledge of minor-cannabinoid detection windows was limited. The results were not a large, blinded forensic validation study designed to establish the accuracy of a source-identification rule. Scheunemann et al., results and limitations.

Source, exposure, impairment, and causation are four different questions

Measurement: Which compounds were detected, in what specimen, at what concentrations, and with which analytical uncertainty? Exposure inference: Is the observed pattern consistent with a described product or route? Functional impairment: Is there reliable evidence of diminished performance at the relevant time? Causation: Did an exposure contribute to the specific conduct or outcome alleged?

Evidence answering one question does not automatically answer the others. This serum-profiling study investigated possible exposure-source patterns; it did not establish an impairment threshold, test driving performance, determine causation, or validate distinctions between legal and illegal possession in any U.S. jurisdiction. For the separate evidentiary issue of screening versus impairment, see Cannabis Roadside Screening: Sensitivity Is Not Impairment. For a discussion of why a detected cannabinoid cannot precisely date use, see Residual THC in Frequent Cannabis Users.

Questions worth asking before offering a forensic source opinion

Was the specimen serum or whole blood? Were the full panel and measured concentrations disclosed, including limits of detection and quantification? Did the laboratory have validated methods for each minor cannabinoid? Is a proposed THC-OH/THC or CBD/THC cutoff derived from a sufficiently similar population and dosing route? Were sample timing, prior exposure, product formulation, analytical uncertainty, and competing sources considered? Has the laboratory demonstrated a false-classification rate for the specific claimed conclusion—or only exploratory separation of study groups?

Those questions are distinct from whether the chemical measurements themselves are accurate. For the broader process of reviewing laboratory materials, see How to Review a Toxicology Laboratory Packet.

Frequently asked questions

Can a positive THC test tell whether cannabis was prescribed?

No. A positive THC result identifies a chemical measurement, not the legal or medical provenance of the product. Even expanded serum panels did not distinguish THC-rich prescribed flower from street cannabis in this pilot study.

Can serum testing suggest dronabinol or Sativex use?

Potentially. A combination of THC metabolite ratios and minor-cannabinoid measurements showed patterns associated with those formulations in a small pilot population. “Consistent with” is more defensible than “proves,” and case-specific interpretation requires independent validation.

Does an 11-hydroxy-THC/THC ratio above 1 prove oral THC?

No. It can be compatible with some oral or oromucosal exposures, but the study did not validate a universal binary threshold for route, product, or dose identification.

Does the presence of THCAA or other minor cannabinoids prove illicit marijuana use?

No. Minor cannabinoids can occur in plant cannabis products used medically and, at low levels, in some manufactured cannabis-based medicines. Presence alone does not determine product provenance.

Can the study establish driving impairment from serum THC?

No. The investigators studied cannabinoid concentration patterns and possible sources, not a driving-performance threshold or causal link to an event.

Primary scientific reference

Scheunemann A, Elsner K, Germerott T, Groppa S, Hess C, Miederer I, Poplawski A, Röhrich J. Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples. Metabolites. 2021;11(5):316. https://doi.org/10.3390/metabo11050316. PMID: 34068332.

Research summary

A systematic review encompassing 101 studies compared roadside screening methods with laboratory cannabinoid testing. Oral-fluid tests had promising performance for detecting THC, although sensitivity varied across devices. A chemical screening result identifies possible exposure or drug presence under defined testing conditions; it does not independently establish functional driving impairment. Confirmation, assay characteristics, matrix, and timing must be evaluated separately.

Forensic interpretation

This research describes specific experimental conditions. It does not establish an individual driver’s impairment or the cause of an observed clinical finding without case-specific information. Analytical methodology, timing, dose, route of administration, and plausible alternative explanations should be assessed before making a forensic inference.

Primary research

Read the peer-reviewed research (PMC PMC10102219).

Alcohol can now be measured or estimated through multiple technologies: evidential breath instruments, laboratory blood testing, consumer breathalyzers, and wearable transdermal sensors. These tools are not interchangeable. Each measures a different specimen or physiological compartment, each has its own time relationship to drinking, and each supports different levels of forensic inference.

Riordan and colleagues compared a cost-effective personal breathalyzer with a police-grade roadside device in 337 young adults outside concerts. The personal device produced a mean reading of 0.085 g/dL compared with 0.077 g/dL on the police-grade instrument, with an average positive bias of approximately 0.008 g/dL. The authors concluded that personal devices may be useful in field research, while the observed bias underscores why a consumer device should not automatically be treated as equivalent to an evidential instrument.

Wearable alcohol monitoring introduces a different measurement problem. Jalal and colleagues developed a pilot transcutaneous alcohol monitoring device and a diffusion model designed to interpret alcohol moving through the skin. Their results support the feasibility of real-time wearable monitoring, but they also show why transdermal values require modeling. Skin thickness and diffusion dynamics affect how quickly the signal changes, and the transcutaneous curve does not simply duplicate a contemporaneous blood concentration.

That lag matters in legal interpretation. A wearable can be powerful evidence of a pattern of alcohol exposure over time, but the exact relationship between a transdermal signal and blood alcohol at a specific minute may require device-specific validation and modeling. A monitor that is excellent at showing that alcohol was consumed may be less suited to proving an exact blood concentration at a disputed instant.

Blood testing presents a different evidentiary profile. When collected and analyzed properly, blood or serum testing can provide a highly precise ethanol concentration for the specimen and time tested. The major interpretive uncertainty often arises afterward: what does that later concentration imply about an earlier event? That question is pharmacokinetic, not merely analytical.

The most useful way to evaluate any alcohol-measurement technology is to ask five questions: What biological compartment is being measured? How was the device calibrated? What is the known bias or uncertainty? What is the expected time lag relative to blood? And is the conclusion being offered one the device was actually validated to support?

Those questions help prevent a common evidentiary error—treating every alcohol number as though it were the same kind of number. A consumer breath reading, an evidential breath result, a laboratory blood value, and a transdermal estimate may all be relevant while carrying very different scientific weight.

For lawyers and experts, the goal is not to reject new technology or accept it uncritically. The goal is method-specific interpretation: understand what was measured, how it was measured, and how far the result can reasonably be extended.

Frequently Asked Questions

Are personal breathalyzers accurate enough for court?

Accuracy varies by device and use conditions. One field study found a measurable positive bias versus a police-grade device. Evidentiary use requires scrutiny of the specific instrument, calibration, procedure, and governing standards.

Does a wearable alcohol monitor measure blood alcohol directly?

No. Transdermal devices detect alcohol migrating through the skin and use sensor response and modeling to interpret exposure over time.

Selected Research

Riordan BC, et al. Digital Health. 2017. doi:10.1177/2055207617746752.

Jalal AH, et al. Sensors. 2024. doi:10.3390/s24134233.